5 amino 1mq 10mg dosage Selective and membrane-permeable small molecule

The therapeutic window is 1025mg/mL for most research peptides, including 5-Amino-1MQ

Impaired activity of methionine synthase results in elevated blood concentrations of homocysteine, while impaired activity of L-methylmalonyl-CoA mutase results in increased concentrations of a metabolite of methylmalonyl-CoA called methylmalonic acid (MMA) in blood and urine

Published April 4, 2012

The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)